Schizophrenia in the 21st century: new insights and translation into improved therapies

Research output: Contribution to journalEditorial

2 Citations (Scopus)

Abstract

Over 100 years have elapsed since schizophrenia was first described and over 50 years since chlorpromazine was utilised to alleviate hallucinations and delusions characteristic of the disorder. With the introduction of a swathe of antipsychotic drugs from the 1970s to date, there have been waves of optimism for improvements in the clinical efficacy of these drugs. Unfortunately, these treatments have not fulfilled expectations. As with chlorpromazine, current medications provide relief for the positive symptoms through dopamine D2 receptor antagonism, but have limited impact on the negative symptoms and cognitive deficits. Moreover, potential drug-induced side effects such as motor dysfunction and weight gain are highly undesirable. Lack of understanding of the causes of schizophrenia together with the continued use of dopamine-based preclinical models in drug discovery, with read-outs of limited translational relevance, are arguably key factors in the lack of major breakthroughs for improved treatments.
LanguageEnglish
Pages83-84
Number of pages2
JournalJournal of psychopharmacology (Oxford, England)
Volume29
Issue number2
DOIs
Publication statusPublished - 1 Feb 2015

Fingerprint

Chlorpromazine
Schizophrenia
Neurobehavioral Manifestations
Delusions
Dopamine D2 Receptors
Hallucinations
Drug Discovery
Drug-Related Side Effects and Adverse Reactions
Antipsychotic Agents
Weight Gain
Dopamine
Therapeutics
Pharmaceutical Preparations
Optimism

Keywords

  • schizophrenia
  • schizophrenia treatments
  • drug discovery

Cite this

@article{6d5cd16f0dfe4035b4ef7b7f3e1a91b8,
title = "Schizophrenia in the 21st century: new insights and translation into improved therapies",
abstract = "Over 100 years have elapsed since schizophrenia was first described and over 50 years since chlorpromazine was utilised to alleviate hallucinations and delusions characteristic of the disorder. With the introduction of a swathe of antipsychotic drugs from the 1970s to date, there have been waves of optimism for improvements in the clinical efficacy of these drugs. Unfortunately, these treatments have not fulfilled expectations. As with chlorpromazine, current medications provide relief for the positive symptoms through dopamine D2 receptor antagonism, but have limited impact on the negative symptoms and cognitive deficits. Moreover, potential drug-induced side effects such as motor dysfunction and weight gain are highly undesirable. Lack of understanding of the causes of schizophrenia together with the continued use of dopamine-based preclinical models in drug discovery, with read-outs of limited translational relevance, are arguably key factors in the lack of major breakthroughs for improved treatments.",
keywords = "schizophrenia, schizophrenia treatments, drug discovery",
author = "Judith Pratt",
year = "2015",
month = "2",
day = "1",
doi = "10.1177/0269881114566743",
language = "English",
volume = "29",
pages = "83--84",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
number = "2",

}

Schizophrenia in the 21st century : new insights and translation into improved therapies. / Pratt, Judith.

In: Journal of psychopharmacology (Oxford, England), Vol. 29, No. 2, 01.02.2015, p. 83-84.

Research output: Contribution to journalEditorial

TY - JOUR

T1 - Schizophrenia in the 21st century

T2 - Journal of Psychopharmacology

AU - Pratt, Judith

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Over 100 years have elapsed since schizophrenia was first described and over 50 years since chlorpromazine was utilised to alleviate hallucinations and delusions characteristic of the disorder. With the introduction of a swathe of antipsychotic drugs from the 1970s to date, there have been waves of optimism for improvements in the clinical efficacy of these drugs. Unfortunately, these treatments have not fulfilled expectations. As with chlorpromazine, current medications provide relief for the positive symptoms through dopamine D2 receptor antagonism, but have limited impact on the negative symptoms and cognitive deficits. Moreover, potential drug-induced side effects such as motor dysfunction and weight gain are highly undesirable. Lack of understanding of the causes of schizophrenia together with the continued use of dopamine-based preclinical models in drug discovery, with read-outs of limited translational relevance, are arguably key factors in the lack of major breakthroughs for improved treatments.

AB - Over 100 years have elapsed since schizophrenia was first described and over 50 years since chlorpromazine was utilised to alleviate hallucinations and delusions characteristic of the disorder. With the introduction of a swathe of antipsychotic drugs from the 1970s to date, there have been waves of optimism for improvements in the clinical efficacy of these drugs. Unfortunately, these treatments have not fulfilled expectations. As with chlorpromazine, current medications provide relief for the positive symptoms through dopamine D2 receptor antagonism, but have limited impact on the negative symptoms and cognitive deficits. Moreover, potential drug-induced side effects such as motor dysfunction and weight gain are highly undesirable. Lack of understanding of the causes of schizophrenia together with the continued use of dopamine-based preclinical models in drug discovery, with read-outs of limited translational relevance, are arguably key factors in the lack of major breakthroughs for improved treatments.

KW - schizophrenia

KW - schizophrenia treatments

KW - drug discovery

UR - http://jop.sagepub.com/content/29/2/83

U2 - 10.1177/0269881114566743

DO - 10.1177/0269881114566743

M3 - Editorial

VL - 29

SP - 83

EP - 84

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 2

ER -